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ABSTRACT We have identified a myelin basic protein
(MBP) isoform in mouse embryos that includes an exon up-
stream of the usual transcription initiation site. This isoform,
embryonic-neonatal MBP (E-MBP), is expressed at the protein
level in the embryonic nervous system at a time when other
MBP isoforms are not detected. In addition to the central and
peripheral nervous systems of the embryo and neonate, the
thymus, spleen, and testes also express E-MBP at the protein
level. The expression of E-MBP in cell types distinct from the
nervous system strongly suggests that this MBP isoform has a
role apart from the formation of myelin.
During the development of the mammalian nervous system,
myelination of neuronal axons is accomplished by specific
glial cells, oligodendrocytes and Schwann cells, which coor-
dinately regulate the expression of a unique set of genes that
are required for the synthesis of the myelin sheath (1). Each
oligodendrocyte, derived from the neuroepithelium, myelin-
ate a number of internodes in the central nervous system
(CNS), while each Schwann cell developed from the neural
crest, myelinates a single internode of an axon of the periph-
eral nervous system (PNS). Between oligodendrocytes and
Schwann cells there is expression of an overlapping set of
myelin-specific genes that are particularly interesting be-
cause they are activated in different cell types that have
unique cell lineages. One member of this class of genes,
myelin basic protein (MBP), is required for normal CNS
myelinogenesis, since an autosomal recessive mouse muta-
tion, shiverer (shi/shi), a deletion of about 60%o of the MBP
gene, leads to severe hypomyelination of the CNS (2).
Normal compact myelin is seen in transgenic shiverer mice,
which have integrated the wild-type MBP gene (26).
In the mouse, the primary MBP transcript is alternatively
spliced by the removal of specific exons to produce mRNAs
encoding at least five different protein isoforms (3-5). An
additional minor MBP mRNA isoform has been isolated by
cDNA cloning of PCR products; however, it is not known
whether this mRNA is actually translated into a 19.7-kDa
protein (6). It has also been reported that several additional
putative exons are located 5' to the previously defined MBP
gene (7, 8, 23). MBP gene expression has been detected at
about postnatal day 7, peaking at about 18 days and decreas-
ing to steady-state levels at about 30 days. In the PNS MBP
mRNA is also detected postnatally.
Thus, MBP gene expression occurs specifically in two
distinct cell types with two separate lineages in both a
temporally and spatially regulated manner to produce gene
products that are essential for the normal development and
function of the nervous system. We used a sensitive and
semiquantitative reverse transcriptase (RT)-PCR assay (9-
11) to measure the expression ofthe various isoforms ofMBP
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mRNA during development of the CNS and PNS. We found
that MBP gene expression begins much earlier than has been
measured previously. We also identified an embryonic-
neonatal-specific isoform (E-MBP) that is expressed not only
in the developing CNS but also in a number of other embry-
onic tissues as both mRNA and protein. This isoform con-
tains at least one novel exon from the promoter region of the
MBP gene. The expression of this isoform in nonmyelinating
cell types suggests an additional function for the E-MBP
isoform apart from a role in myelinogenesis.
MATERIALS AND METHODS
Mice. Embryos and neonates were collected from naturally
mated BALB/c mice. The day of plug was embryonic day 0
(EO).
cDNA Synthesis and PCR Amplffication. Total RNA was
isolated from brains or sciatic nerves of staged mice with
guanidine isothiocynate and CsCl (12, 13). Brain cDNA was
synthesized from 1 Mg of freshly prepared total RNA per
cDNA reaction mixture in 1 x first-strand buffer [50mM Tris,
pH 8.3/50 mM KCl/10 mM MgCl2/1 mM dithiothreitol/l
mM EDTA/0.5 mM spermidine hydrochloride/4mM sodium
pyrophosphate/1 mM dNTPs, containing bovine serum al-
bumin (10 t&g/ml) and RNasin (1 x 10-3 unit/,I, Promega)]
with oligo(dT) as a primer for RT (275 units/ml, Molecular
Genetic Resources, Tampa, FL). A cDNA aliquot was di-
luted 10-fold and used for PCR. Each PCR mixture contained
5 .ul diluted cDNA along with MBP-specific primers (2 ,uM),
actin-specific primers (2 ,uM), or glyceraldehyde-3-
phosphate dehydrogenase (G3PDH)-specific primers (0.7
,uM) (Clontech), dNTPs (0.2-mM), lx PCR buffer [50 mM
KCl/10 mM Tris, pH 8.4/3 mM MgCl2 with gelatin (100
,ug/ml)], 2.5 units of Taq polymerase (AmpliTaq DNA poly-
merase, Perkin-Elmer/Cetus), and 5-,Ci of [a-32P]dCTP
(800 Ci/mmol, Amersham; 1 Ci = 37 GBq). The PCR
amplification was carried out for 30 cycles of either 30 sec at
95°C, 30 sec at 66°C, 60 sec at 72°C or 30 sec at 95C, 60 sec
at 72°C, depending on the "melting" temperature of the
specific primers used. The resulting PCR products were
analyzed by electrophoresis in a4% Hydrolink P600 gel (J. T.
Baker), which was dried and exposed to x-ray film. The
relative level of each amplified PCR product was quantified
with a Phosphorlmager (Molecular Dynamics). Although
some of the signals may appear to exceed the linear range of
x-ray film, they were in the linear range of the Phosphorlm-
ager.
Abbreviations: MBP, myelin basic protein; CNS, central nervous
system; PNS, peripheral nervous system; RT, reverse transcriptase;
En, embryonic day n; Pn, postnatal day n.
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Oligodeoxynucleotide primers were as follows (sequences
are shown 5' to 3').
MBP 5' primers
MBP 3' primers
Actin 5' primer
Actin 3' primer
Embryonic primer
G3PDH5' primer
G3PDH3' primer
pro3
start
term
end7
actl22
actl23
wzl
G3PDHS'
G3PDH3'
CCGGAGGCCTGGATGTGATG
GCATCACAGAAGAGACCCTCACAGC
TCAGCGTCTCGCCATGGGAG
ATCCAGAGCGGCTGTCTCTCTTCCTCC
GTTGTCGACGACCAGCGCAGCG
CCTCCATCGTGCACCGCAAGT
GGAACCGCCCCCACTTGATCCGCCT
TGAAGGTCGGTGTGAACGGATTTGGC
CATGTAGGCCATGAGGTCCACCAC
Western Blots. Brain homogenates were prepared as de-
scribed (14). Samples were electrophoresed in a 15% poly-
acrylamide Mini-Protean gel system (Bio-Rad), and the sep-
arated proteins were electrotransferred to a poly(vinylidene
fluoride) membrane and used immediately with MBP exon-
specific antibodies. Exon-specific antibodies were prepared
by immunizing rabbits with synthetic peptides that corre-
sponded to various exons of MBP [MBP embryonic exon
peptide; RLFSRDAPGREDNTFKDRPSC; MBP exon 1
peptide; ASQKRPSQRSKYLATASTMDC; cysteine (C)
was added to the carboxyl termini for conjugation to the
carrier protein]. After the blot was blocked with bovine
serum albumin, streptavidin, and biotin, protein bands were
visualized by reaction with anti-rabbit goat secondary anti-
body conjugated to biotin and streptavidin conjugated to
alkaline phosphatase, followed by a mixture of 5-bromo-4-
chloro-3-indolyl phosphate and nitro blue tetrazolium. Alter-
natively, the reactions used anti-rabbit goat secondary anti-
body conjugated directly to alkaline phosphatase (Boehringer
Mannheim and Pierce).
RESULTS
RT-PCR Assay of MBP Isoforms. We used semiquantita-
tive RT-PCR to measure the appearance and subsequent
expression of all the MBP mRNA isoforms during mouse
development. The sensitivity of RT-PCR was very high,
since we were able to detect transcripts in at least 10,000-fold
dilution of an aliquot of brain cDNA that was typically used
in these experiments (data not shown). Fig. 1A represents
schematically the expected PCR products when primers are
targeted in exons 1 and 7, and their corresponding MBP
isoforms. To establish the subsaturation levels of input
cDNA and the PCR cycle number, the relative expression
level of each MBP isoform was compared with an internal
standard generated with actin-specific primers multiplexed
with the MBP primers (Fig. 1B). In addition, there was no
significant change in the amplification efficiency of the actin
and MBP primers when the two sets of primers were multi-
plexed (Fig. 1C).
Developmental Expression of MBP Isoforms mRNA in the
CNS. BrainRNA from embryonic (E) and postnatal (P) stages
ofmouse development (days E14, E18, P0, P6, P10, P18, P30,
P90, and P162) was converted intocDNA PCR-amplified with
MBP-specific and actin-specific primers (Fig. 2). When the
relative expression of each MBP mRNA isoform was nor-
malized to actin expression, it was found that the expression
pattern of all the MBP mRNA isoforms could be divided into
two categories. The first category (21-, 18.5-, 17.2-, and
14-kDa isoforms) began their expression at low levels at
various developmental stages and then increased to peak
levels at about P18. This peak period lasted until P20 (data not
shown). This was followed by decreasing levels on an aver-
age of about 50% to a steady-state level where the expression
pattern remained constant throughout the life of the animal.
The second category of MBP mRNA isoform expression
also began at various developmental stages; however, the
expression of these isoforms peaked at about P10 and was
undetectable by P18. This category was exemplified by the
17.3-kDa MBP isoform in addition to a minor MBP mRNA
A 5' primers: -) -e
exon 1 exon 7 MBPmRNA
4- v- 3 primers
MBP m?,nRNiA Isoforms Expected size
ofPCR product
1 2 3 4 5 6 7
21 kDa IZl-5=Ze-.S//. 777R.\ 598
1 3 4 5 6 7 520
18.5 kDa "I I L
1 3 4 6 7
17.3 kDa ; I 477
1 2 3 4 5 7
17.2 kDa ........ 465
1 3 4 5 7
14 kDa { 397
B
Cycle # cDNA
'A ar i n r
-RT
(bp)
598 q
520 4
477
465 X
397
1 2 3 4 5
C
Primers: QAAo
Actin _
(bp)
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520
_I _477
465 _
397w s
1 2 3 4
FIG. 1. (A) The corresponding molecular mass of each peptide is
shown along with the expected size of the DNA product (in base
pairs) when exon 1-specific (pro3) and exon 7-specific (term) primers
(arrows) are used in PCR amplification. Hatching and crosshatching
indicate differentially spliced exons. (B) P18 brain RNA was con-
verted into cDNA and PCR-amplified with [a-32P]dCTP. In lane 2 the
cycle number was increased by 5 cycles. In lane 3 twice the amount
of cDNA (10 ,l) was used as for lane 4 (5 /4). Lane 5 is a PCR
amplification with P18 cDNA that was synthesized without RT. (C)
P18 brain cDNA was PCR-amplified with the primers indicated. Lane
3 is a PCR amplification multiplexed with MBP-specific and actin-
specific primers (actl22 and actl23), producing the five MBP-
specific products along with the actin-specific product (1000 bp).
Lane 4 is a MBP-actin PCR multiplex using P18 cDNA prepared
without RT.
isoform, of 19.7 kDa. One of the most interesting patterns of
expression was displayed by a member of this second cate-
gory ofMBPmRNA isoform expression that corresponded to
a PCR product of about 375 bp. This species was detected as
early as E14, much earlier than previously measured forMBP
gene expression, and was almost undetectable at P18. Be-
cause this MBP mRNA isoform was expressed during em-
bryonic and early neonatal development, it was termed the
embryonic-neonatal (E-MBP) MBP isoform.
Given their low signal, we wished to verify that MBP
mRNA isoforms were indeed present at these earlier embry-
onic stages. For this purpose, embryonic and neonatal brain
Proc. Natl. Acad. Sci. USA 90 (1993)
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FIG. 2. RNA was isolated from the brains of developmentally
staged mice, converted into cDNA and PCR-amplified with
[a-32P]dCTP and MBP-specific primers (pro3 and term) and actin-
specific primers (actl22 and actl23). Only the P18 no-RT control is
shown.
RNAs were converted into cDNA and amplified without
[a-32P]dCTP. An aliquot was then reamplified with
[a-32P]dCTP with a second set of nested MBP primers. The
resulting PCR products indicated that in addition to E-MBP
mRNA, transcripts encoding the 14-, 17.3-, and 21-kDa
isoforms were also present in the embryonic brain (Fig. 3,
lanes 1 and 2). By the time other MBP mRNA isoforms had
reached peak levels of expression, the E-MBP mRNA iso-
form was almost undetectable (Fig. 3, lane 4). Since the MBP
mRNA isoforms began and terminated their expression at
different times during development, three distinct patterns of
MBP mRNA isoforms were seen in the embryo (21, 17.3, and
14 kDa and E-MBP), neonate (21, 19.7, 18.5, 17.3, 17.2, and
14 kDa and E-MBP), and adult (21, 18.5, 17.2, and 14 kDa).
The MBP isoforms expressed in the PNS was also examined.
From RNA isolated from neonatal (P6 and P10) sciatic
nerves, cDNA was synthesized and PCR-amplified with
MBP- and actin-specific primers. All the MBP isoforms
Secondary Primary
cDNA: E14 E18 P0 P20
thn)5u9)
598
520
477
465
397
375
1 2 3 4 5 6
FIG. 3. Brain cDNA was prepared from tissues at various stages
of development and PCR-amplified without [a-32P]dCTP using pro3
and term primers. An aliquot was removed from each PCR mixture
and amplified with a set of nested primers (start and end7) with
[a-32P]dCTP. A primary amplification of P18 cDNA with
[a-32P]dCTP was electrophoresed in an adjacent lane on the gel. MBP
isoforms are indicated by molecular size (length, bp) of PCR prod-
ucts.
detected in the CNS were also expressed in the PNS,
including the E-MBP isoform (data not shown).
The E-MBP Isoform Contains a Novel Exon. Our laboratory
has identified a putative exon located 5' to the transcription
initiation site of the MBP gene, by its similarity between the
mouse and shark 5' regions of the MBP gene. This exon was
termed the "wobble zone" (see Fig. 4A) (7) and it was
postulated that since this region was so highly conserved at
the protein level, it was highly likely to represent a coding
region. A MBP cDNA clone that also contains sequences 5'
to the transcription initiation site of the MBP gene has also
been reported (8). To determine whether the wobble zone
was used in any MBP isoforms, RT-PCR assays were per-
formed with wobble zone-specific primers.
When brain cDNA from a neonate was amplified with a
wobble exon-specific primer and an exon 7-specific primer,
a major PCR product of about 520 bp was produced along
with a minor product of about 500 bp (Fig. 4B). We have not
identified the minor PCR product but suspect that it may be
a product of alternative RNA splicing. These two primers
were used to produce a nonradioactive amplification product
that was isolated as a single 520 bp band from an agarose gel.
When the 520-bp PCR product was then reamplified with the
exon 1 and exon 7 primers and [a-32P]dCTP, the E-MBP
mRNA isoform was detected, indicating that the wobble exon
was spliced to only the E-MBP isoform (Fig. 4B). E-MBP
mRNA isoform expression is restricted to the embryo and the
neonate, since the same experiments performed with P30,
P60, or P90 brain cDNA yielded no detectable PCR products.
Since only the E-MBP mRNA isoform contains the wobble-
zone exon, we now refer to this exon as the embryonic exon.
Expression ofMBP Peptide Isoforms in the CNS. To ensure
that these MBP mRNA isoforms were translated, SDS ho-
mogenates of developmentally staged brains were analyzed
by Western blots with anti-MBP antibodies prepared against
synthetic peptides encoded by specific exons. An exon
1-specific antibody recognized the 21-, 18.5-, 17.2-, and
14-kDa MBP isoforms normally observed in the adult brain
(Fig. SA). However, a major peptide of -16 kDa was detected
from E18 to P6 and was almost completely absent by P10.
When the same set of brain homogenates was probed with an
antibody prepared against a peptide that corresponded to the
translation product of the embryonic exon, a 16-kDa peptide
was detected from E18 to P6. This protein began to disappear
at P10 and was undetectable by P30 (Fig. 5B). The predicted
size of a protein translated from the E-MBP PCR product
derived from exon 1 and exon 7 primers and added to the
translation product of the embryonic exon was estimated to
be a protein of about 16 kDa, which matches the size of the
peptide observed in the Western blots. Thus, the E-MBP
isoform was translated in the developing brain concomitantly
to the expression of its putative mRNA. The other MBP
isoforms appeared during development coinciding with the
beginning of active myelination of the CNS at P6 or later, but
not concomitantly with the expression of their respective
mRNA isoforms.
Expression ofE-MBP in Non-Brain Tissues. When homoge-
nates from a variety of embryonic and neonatal tissues were
probed with the embryonic exon-specific antibody, the
E-MBP isoform was detected in liver, spleen, testes, and
thymus (Fig. SC). Thus, the E-MBP isoform was widely
expressed as a 16-kDa peptide in a number of distinct cell
types, apart from the nervous system, which are not asso-
ciated with myelination.
DISCUSSION
Seven MBP mRNA Isoforms Are Differentiafly Expressed
During Development. We have shown that there are two
categories of differential expression ofMBPmRNA isoforms
Neurobiology: Mathisen et al.
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FIG. 4. (A) The sequence of the embryonic exon. Underlined
sequences are the MBP promoter's putative CAAT and TATA
boxes. (B) PCR amplification of brain cDNAs prepared from devel-
opmentally staged mice. Lanes 1-3 used an embryonic exon-specific
5' primer (wzl) and an exon 7-specific 3' primer (term) with
[a-32P]dCTP added. Lane 4 is an amplification ofa PCR product that
was produced from an amplification with wzl and term. For lanes
4-7, amplification with the 5' primer was in exon 1 (pro3) and the 3'
primer was in exon 7 (term), and [a-32P]dCTP was added. This
amplification produced a single band corresponding to the 375-bp
E-MBP mRNA isoform (lane 5).
during development. The first category, including mRNAs
encoding the 21-, 18.5-, 17.2-, and 14-kDa MBP isoforms,
initiates synthesis at varying stages of development, rises to
a peak during maximal myelination, at P18, and then declines
to approximately half this level for the remainder of the
animal's life. The second category ofMBP isoforms initiates
synthesis prior to birth and is then absent at peak myelination
(P18). This differential expression results in distinct combi-
nations of MBP mRNA isoforms expressed in the embryo,
neonate, and adult. One of the surprising results of this study
was the detection of MBP gene expression in the early
embryo. Although other studies have found that the earliest
expression ofMBP is only in the medulla of the newborn (15,
16), we found expression as early as E14 in all regions of the
brain examined (data not shown).
Since MBP mRNAs and the E-MBP protein are expressed
in the embryo at a time when oligodendrocytes have not yet
16 -__- _ .M
1 2 3 4 5 6 7 8 9
FIG. 5. (A) Western blot of brain homogenates from develop-
mentally staged mice probed with an antibody against an exon 1
peptide. Molecular masses (kDa) are indicated at the sides. (B)
Similar blot probed with an antibody against an embryonic-exon
peptide. (C) Western blot of various tissue homogenates prepared
from either E18 or PO mice and probed with an antibody against the
embryonic exon peptide. As controls, brain and liver lanes that were
probed with the secondary antibody only are shown (lanes 8 and 9).
developed, MBP gene expression may be activated in oligo-
dendrocyte precursor cells. CNS progenitor cells would then
be committed in the embryo to an oligodendrocyte lineage
rather than later during neonatal development. 0-2A cells,
oligodendrocyte precursors present in the embryo as early as
E15, can differentiate in vitro into either oligodendrocytes or
the nonmyelinating type II astrocytes (17). The embryonic
expression ofMBP indicates that in vivo the embryonic 0-2A
cells may already be committed to differentiate into oligo-
dendrocytes. Although oligodendrocyte differentiation is
thought to proceed cell-autonomously, it has been shown that
oligodendrocytes and oligodendrocyte precursor cells are
responsive to a number ofgrowth factors (18-21). Thus, MBP
gene expression may be activated at low levels in an oligo-
dendrocyte precursor (0-2A cells) that would then await for
an induction signal that increases the MBP mRNA levels to
those observed in P18 mouse brain.
E-MBP Is Present in Embryonic Tissues and May Have
Functions Apart from Myelination. Perhaps the most striking
observation was the identification of an isoform expressed
only during embryonic and neonatal development. The
E-MBP mRNA isoform was detected as early as E14, in-
creased to a maximum level of expression at P6 and then
A
q:7-
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decreased before active myelination (P18) to undetectable
levels. This isoform contains an exon that appears to be
expressed only in the embryo and neonate and that is located
just upstream of exon 1 in the MBP gene. E-MBP was also
expressed at the protein level in a number of embryonic
tissues, including the thymus, spleen, and testis. The expres-
sion of E-MBP in the embryonic nervous system at a time
when there is no myelination or expression of other MBP
isoforms and the wide distribution of E-MBP in other em-
bryonic tissues, in addition to the presence of the embryonic
exon, are distinct features of the E-MBP isoform. Since
E-MBP is present prior to myelination and is expressed in cell
types that do not myelinate (e.g., thymus and spleen), it must
perform a function other than compaction during myelina-
tion. Given its ubiquitous expression in other embryonic
tissues, it may be involved in some aspect of differentiation
that is not required in the adult. In fact, alternative splicing
of exon 2 of the MBP gene may be responsible for the
differential intracellular localization of MBP isoforms in the
CNS (22).
A number of questions arise about the regulation of MBP
expression. MBP transcription must require at least two
separate promoters, since the embryonic exon overlaps and
extends upstream of the normal transcription start site of the
MBP gene (Fig. 4A). Transcription of the E-MBP isoform
would utilize an upstream initiation site and promoter region
to include the embryonic exon in the E-MBP mRNA. Cam-
pagnoni et al. (23) have shown that additional 5' exons of the
MBP gene produce transcripts that initiate transcription
much farther upstream than the previously defined MBP gene
and are called Golli-mbp. E-MBP has some ofthe same exons
as the Golli transcript (data not shown). The nature of the
production of the six previously identified MBP RNA iso-
forms poses interesting challenges to the control of alterna-
tive forms of mRNA by RNA splicing. Finally, in the
embryonic CNS we have detected the 21, 17.2, and 14-kDa
and the E-MBP mRNA isoforms; however, during the em-
bryonic phase of MBP expression only the E-MBP mRNA
isoform is translated into a peptide. Thus, there is a regula-
tory mechanism in the embryonic brain that selectively
allows only the E-MBP mRNA to be translated. Translation
ofMBP mRNAs has been shown to be stimulated by steroids
through a steroid response element located in the 5' end ofthe
MBP mRNA, between nucleotides -29 and -73 (24). The
E-MBP mRNA isoform contains this sequence and may have
additional 5' sequence(s) that are responsible for its selective
translation in the embryo.
The high level expression of the E-MBP isoform peptide,
particularly in the thymus and spleen, raises an interesting
question in regard to tolerance to MBP (25). It is not known
how animals become tolerant to MBP in the embryo, since
MBP expression is sequestered by the blood-brain barrier.
However, since the E-MBP isoform is widely expressed in
the embryo at a time when tolerance mechanisms are most
active and in the thymus, which is presumably responsible for
tolerance induction, this could be one way of producing
tolerance to MBP.
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